Study - Enrolling
Moderate-to-Severe Atopic Dermatitis Clinical Trials
Itch that never quits wears you down day and night. Find out if this atopic dermatitis research study in Colorado is a next step for you or your teen.
About this study
Moderate-to-Severe Atopic Dermatitis clinical trials like this Phase 3 study in Colorado test an investigational treatment against a placebo in people 12 and older with moderate-to-severe disease. Researchers measure changes in symptoms and skin severity, and they monitor safety and tolerability. The main assessment comes at Week 24 of the study.
Who may be able to take part?
Teens and adults ages 12 and older living with moderate to severe atopic dermatitis may be a fit for this eczema clinical study in Colorado, as long as they show a certain level of skin involvement. At your screening visit, the PRG study team walks through every eligibility requirement and answers all your questions before you decide.
What participation may involve?
Screening comes first. Then you are randomly assigned to the study drug or a placebo, and neither you nor the team knows which. Clinic visits cover skin checks, lab work, and symptom updates, and you log your itch and flares in between. Taking part may help bring an atopic dermatitis treatment option closer to the people who need it.
Curious about eczema clinical trials? Bring these questions along to your screening visit with the study team:
Could I get the placebo, and when will I find out?
How often are clinic visits, and what do skin assessments and lab work involve?
How do I track my itch and flares, and who do I call if my symptoms get worse?
Questions to ask the study team
Study at a glance
Study Status
Recruiting
Age
Adults aged 12 and older
Location
Colorado
We're Here to Help!
Thinking about joining a research study but not sure where to start? We're happy to answer your questions, walk you through the process, and help you explore whether a study is right for you.
Frequently Asked Questions
-
The study is a Phase 3 clinical trial evaluating rezpegaldesleukin as a potential Atopic Dermatitis treatment option for people ages 12 and older with moderate to severe symptoms. The study compares the study drug against a placebo to measure safety and effectiveness over time.
-
Eligibility generally includes people ages 12 and older with a confirmed diagnosis of moderate to severe atopic dermatitis, along with a certain level of skin involvement. A member of the study team reviews full eligibility criteria during screening.
-
This study is currently recruiting participants at sites across Colorado. Reach out to the study team to check nearby locations, review eligibility, and learn what participation involves before enrolling.